| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/10/2013 | US20130012434 Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
| 01/10/2013 | US20130012433 Method for reducing cardiovascular morbidity and mortality in prediaetic patients and patients with type 2 diabetes |
| 01/10/2013 | US20130012432 Peptides for Treatment of Obesity |
| 01/10/2013 | US20130012431 Method For Elevating Prolactin In Mammals |
| 01/10/2013 | US20130012430 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 01/10/2013 | US20130012429 Anti-viral therapy |
| 01/10/2013 | US20130012427 Polypeptides |
| 01/10/2013 | US20130012426 Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For the Treatment of Psoriasis |
| 01/10/2013 | US20130011919 Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof |
| 01/10/2013 | US20130011903 Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities |
| 01/10/2013 | US20130011902 Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibers |
| 01/10/2013 | US20130011488 Systems, Methods, and Formulations for Treating Cancer |
| 01/10/2013 | US20130011465 Composition and method for the treatment of diseases affected by apoptosis |
| 01/10/2013 | US20130011464 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 01/10/2013 | US20130011446 Ceramic composition for filling bone defects |
| 01/10/2013 | US20130011433 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 |
| 01/10/2013 | US20130011428 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/10/2013 | US20130011425 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/10/2013 | US20130011423 Metalloproteinase oligopeptides and their therapeutic use |
| 01/10/2013 | US20130011411 Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| 01/10/2013 | US20130011409 Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 |
| 01/10/2013 | US20130011404 Methods and Compositions for Regulating Musashi Function |
| 01/10/2013 | US20130011399 WAP Domain Fusion Polypeptides and Methods of Use Thereof |
| 01/10/2013 | US20130011398 Serpin Fusion Polypeptides and Methods of Use Thereof |
| 01/10/2013 | US20130011397 Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain |
| 01/10/2013 | US20130011385 Transparent bacterial cellulose nanocomposite hydrogels |
| 01/10/2013 | US20130011382 Fibrinogen Preparations Enriched In Fibrinogen With An Extended Alpha Chain |
| 01/10/2013 | US20130011381 Modified enzyme treatment method |
| 01/10/2013 | US20130011380 Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming |
| 01/10/2013 | US20130011379 Pyridoxamine for the Treatment of Diabetic Kidney Disease |
| 01/10/2013 | US20130011378 Stable formulations of a hyaluronan-degrading enzyme |
| 01/10/2013 | US20130011370 Uniform Field Magnetization and Targeting of Therapeutic Formulations |
| 01/10/2013 | US20130011367 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| 01/10/2013 | US20130011366 Therapeutic Agent for infections, and treatment method using the same |
| 01/10/2013 | US20130011365 Parp inhibitor compounds, compositions and methods of use |
| 01/10/2013 | US20130011361 Pyrazole derivatives which modulate stearoyl-coa desaturase |
| 01/10/2013 | US20130011338 Cupredoxin derived transport agents and methods of use thereof |
| 01/10/2013 | US20130011335 Materials and Methods Related to Sodium/Potassium Adenosine Triphosphate and SRC |
| 01/10/2013 | US20130011334 Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
| 01/10/2013 | US20130011333 Methods and Compositions for Nanoparticle-Mediated Cancer Cell-Targeted Delivery |
| 01/10/2013 | CA2843853A1 Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof |
| 01/10/2013 | CA2841376A1 N-terminal deleted gp120 immunogens |
| 01/10/2013 | CA2841075A1 Multiple-enzyme nanocomplexes |
| 01/10/2013 | CA2840924A1 Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases |
| 01/10/2013 | CA2840905A1 Formulations for wound therapy |
| 01/10/2013 | CA2840876A1 Formulations that stabilize proteins |
| 01/10/2013 | CA2840711A1 Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use |
| 01/10/2013 | CA2839727A1 Systems, methods, and formulations for treating cancer |
| 01/10/2013 | CA2838496A1 Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases |
| 01/10/2013 | CA2835607A1 Compositions, uses and methods for treatment of metabolic disorders and diseases |
| 01/09/2013 | EP2543730A1 Antibody constant region variant |
| 01/09/2013 | EP2543729A1 Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
| 01/09/2013 | EP2543676A1 Cyclical tripeptide mimetics |
| 01/09/2013 | EP2543661A1 Guanylhydrazone compounds, compositions, methods of making and using |
| 01/09/2013 | EP2543390A1 Pharmaceutical composition |
| 01/09/2013 | EP2543385A1 Novel analgesics |
| 01/09/2013 | EP2543384A2 Treatment of conditions involving demyelination |
| 01/09/2013 | EP2543383A1 Macrocyclic compounds and methods of treatment |
| 01/09/2013 | EP2543382A1 Agent for preventing muscular atrophy |
| 01/09/2013 | EP2543340A1 Novel hydrophilic polymers as medical lubricants and gels |
| 01/09/2013 | EP2542703A2 Novel hiv-1 envelope glycoprotein |
| 01/09/2013 | EP2542687A1 Involvement of androgen/androgen receptor pathway in fabry disease |
| 01/09/2013 | EP2542679A1 B-cell stimulating fusion proteins of an antigen with baff or april |
| 01/09/2013 | EP2542590A2 Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| 01/09/2013 | EP2542570A1 Target of egr1 (toe1 ) polypeptides for inhibition of hiv |
| 01/09/2013 | EP2542569A1 Chimeric inhibitor molecules of complement activation |
| 01/09/2013 | EP2542263A2 Ep1 inhibition |
| 01/09/2013 | EP2542255A1 Methods and compositions for treating degos' disease |
| 01/09/2013 | EP2542253A1 Modulation of intracellular signaling |
| 01/09/2013 | EP2542252A1 Hiv-1 envelope based fragments |
| 01/09/2013 | EP2542230A2 Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1 |
| 01/09/2013 | EP2542074A1 Combination pharmaceutical agents as inhibitors of hcv replication |
| 01/09/2013 | CN1642570B Stable pharmaceutical composition containing factor viii |
| 01/09/2013 | CN102869679A Stable MIA/CD-RAP formulation |
| 01/09/2013 | CN102869676A Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability |
| 01/09/2013 | CN102869371A An insulin conjugate using an immunoglobulin fragment |
| 01/09/2013 | CN102869370A Neuregulin based compositions and uses thereof for preventing, treating or delaying the myocardial ischemia-reperfusion injury |
| 01/09/2013 | CN102869369A Methods of use of soluble CD24 for therapy of rheumatoid arthritis |
| 01/09/2013 | CN102869368A Therapeutic use of the beta2m protein |
| 01/09/2013 | CN102869367A Novel cyclic peptides |
| 01/09/2013 | CN102866119A Biological activity detection method of protein of flagellin protein derivative of salmonella and application thereof |
| 01/09/2013 | CN102864154A A group of Cathelicidins antimicrobial peptides of chicken, preparation method and application thereof |
| 01/09/2013 | CN102863538A Fused polypeptide mutant containing protein transduction domain and preparation method thereof |
| 01/09/2013 | CN102863537A Tumor targeting tumor necrosis factor related apoptosis ligand variant and application thereof |
| 01/09/2013 | CN102863525A Recombinant human apoE peptide mimics, preparation method and application |
| 01/09/2013 | CN102863515A B-cell epitope of human melanoma antigen MAGE-A3 and application thereof |
| 01/09/2013 | CN102863514A Peptide vaccines for cancers expressing tumor-associated antigens |
| 01/09/2013 | CN102863512A Novel antiviral compound |
| 01/09/2013 | CN102861360A Neural restoration promoting material as well as preparation method and application thereof |
| 01/09/2013 | CN102861343A Application of secretory type Klotho in preparing medicine for treating chronic renal failure |
| 01/09/2013 | CN102861340A Intelligent nano delivery system, preparation method and application thereof |
| 01/09/2013 | CN102861325A Compositions for reducing bacterial carriage and cns invasion and methods of using same |
| 01/09/2013 | CN102861324A Biological reagent for treating carbapenems resistant acinetobacter baumannii infection |
| 01/09/2013 | CN102861323A A novel blood substitute with complete red blood cell functions |
| 01/09/2013 | CN102861322A Hemoglobin-based oxygen carrier and preparation method thereof |
| 01/09/2013 | CN102861321A Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency |
| 01/09/2013 | CN102861320A Spray for treating skin and mucosa wounds |
| 01/09/2013 | CN102861319A Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| 01/09/2013 | CN102861318A Application of A-type kreotoxin heavy chains to exciting regeneration of neurite |
| 01/09/2013 | CN102861317A Application of salmonella flagellin derivative in preparation of medicines for preventing and treating inflammatory bowel diseases |